http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2727198-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36c66685971b78daf233b5999ead4c2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 |
| filingDate | 2016-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f06a91309547053a18d2482fde98baa4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf34919982acea79464251dd9bafd853 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_985d56db18da5cde0d455356185cc5e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a86dfb8b8da942fb6c1517c20266325d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c55ea76147aac12062b4c63047afc3ab |
| publicationDate | 2020-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2727198-C2 |
| titleOfInvention | Benzofuran derivative, a method for production thereof and use thereof in medicine |
| abstract | FIELD: medicine; pharmaceuticals. n SUBSTANCE: invention relates to a benzofuran derivative of general formula (I), or a pharmaceutically acceptable salt thereof, in which ring A is selected from a group consisting of heterocyclyl, which is 5–6 membered saturated monocyclic hydrocarbon group having one heteroatom selected from N, O and S, and 3–6-member cycloalkyl; each R 1 is identical to or different from the other, and each is independently selected from a group consisting of a hydrogen atom, a halogen atom, C 1-6 -alkyl, halo-C 1-6 -alkyl, cyano, 3–6-member cycloalkyl, 5–6 membered saturated or partially unsaturated monocyclic hydrocarbon group having one N atom and -(CH 2 ) x R a , where 5–6 membered saturated or partially unsaturated monocyclic hydrocarbon group is optionally substituted with one or more groups selected from group, consisting of C 1-6 -alkyl; R a is selected from a group consisting of heterocyclyl which is 5–6 membered saturated monocyclic hydrocarbon group having one or two heteroatoms selected from N and O, and -NR 7 R 8 , where each heterocyclyl is independently and optionally substituted with one or more groups selected from a group consisting of C 1-6 -alkyl, a halogen atom and hydroxy-C 1-6 -alkyl; R 2 is C 1-6 -alkyl, where alkyl is optionally substituted with one or more groups selected from a group consisting of 3–6-member cycloalkyl; R 3 is selected from a group consisting of C 1-6 -alkyl, a halogen atom and halo-C 1-6 -alkyl; each R 4 is identical to the other or different from it, and each is independently selected from a group consisting of a hydrogen atom, C 1-6 -alkyl and C 1-6 -alkoxy; each R 5 is identical to the other or different from it, and each is independently selected from a group, consisting of a hydrogen atom, oxo, a halogen atom, halo-C 1-6 -alkyl, -C(O)R 6 , -S(O) m R 6 and -NR 7 R 8 ; R 6 is selected from C 1-6 -alkyl; R 7 and R 8 are identical or different from each other, and each is independently selected from a group consisting of C 1-6 -alkyl; m equals 2; n equals 2; p is 0, 1 or 2; q equals 0 or 1; and x is equal to 1, 2 or 3. Invention also relates to a method of producing a compound of formula (I) and a pharmaceutical composition having inhibitory activity on EZH2 based thereon. n n n n EFFECT: technical result is obtaining a novel compound and a pharmaceutical composition based thereon, which can be used in medicine for preventing and/or treating diseases, such as tumors and cancer. n 13 cl, 4 tbl, 34 ex |
| priorityDate | 2015-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 318.